Whole brain and segmented CBF and OEF between cohorts
. | No disease-modifying therapy, median (IQR) . | Hydroxyurea therapy, median (IQR) . | Chronic transfusion therapy, median (IQR) . | P . |
---|---|---|---|---|
Cerebral blood flow | (N = 11) | N = 25 | N = 14 | |
Whole brain CBF, mL/100 g/min | 99.8 (82.7-117.7) | 90.8 (74.2-100.2) | 87.0 (75.9-96.4) | .148 |
Gray matter CBF, mL/100 g/min | 112.5 (93.4-130.1) | 97.4 (86.7-109.8) | 94.3 (87.7-112.8) | .312 |
White matter CBF, mL/100 g/min | 60.5 (46.1-81.5) | 55.5 (46.6-66.6) | 51.1 (48.7-55.9) | .274 |
OEF | N = 22 | N = 38 | N = 22 | |
Whole brain OEF, % | 42.9 (39.1-49.1)*,† | 40.7 (34.9-43.6)*,¶ | 35.3 (32.2-38.9)†,¶ | <.001‡ |
Gray matter OEF, % | 44.3 (39.2-49.2)*,† | 41.2 (36.3-44.4)*,¶ | 35.0 (33.2-37.7)†,¶ | <.001‡ |
White matter OEF, % | 42.6 (38.1-48.7)*,† | 39.8 (33.8-43.5)*,¶ | 34.1 (30.8-39.2)†,¶ | <.001‡ |
. | No disease-modifying therapy, median (IQR) . | Hydroxyurea therapy, median (IQR) . | Chronic transfusion therapy, median (IQR) . | P . |
---|---|---|---|---|
Cerebral blood flow | (N = 11) | N = 25 | N = 14 | |
Whole brain CBF, mL/100 g/min | 99.8 (82.7-117.7) | 90.8 (74.2-100.2) | 87.0 (75.9-96.4) | .148 |
Gray matter CBF, mL/100 g/min | 112.5 (93.4-130.1) | 97.4 (86.7-109.8) | 94.3 (87.7-112.8) | .312 |
White matter CBF, mL/100 g/min | 60.5 (46.1-81.5) | 55.5 (46.6-66.6) | 51.1 (48.7-55.9) | .274 |
OEF | N = 22 | N = 38 | N = 22 | |
Whole brain OEF, % | 42.9 (39.1-49.1)*,† | 40.7 (34.9-43.6)*,¶ | 35.3 (32.2-38.9)†,¶ | <.001‡ |
Gray matter OEF, % | 44.3 (39.2-49.2)*,† | 41.2 (36.3-44.4)*,¶ | 35.0 (33.2-37.7)†,¶ | <.001‡ |
White matter OEF, % | 42.6 (38.1-48.7)*,† | 39.8 (33.8-43.5)*,¶ | 34.1 (30.8-39.2)†,¶ | <.001‡ |
Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving HU.
Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving CTT.
Statistically significant.
Significant difference between cohort receiving HU vs cohort receiving CTT.